About
About Ionetix
Medical isotopes, and the accelerators that make them.
Ionetix leverages its proprietary cyclotron and accelerator expertise to produce a growing portfolio of critical medical isotopes for targeted alpha therapy and diagnostic imaging.
For therapeutics, Ionetix is focused on producing high-purity, alpha-emitting therapeutic isotopes, including actinium-225 and astatine-211; the Company ships Ac-225 globally and At-211 in North America.
For diagnostics, Ionetix manufactures Positron Emission Tomography (PET) radiopharmaceuticals through its network of FDA-approved sites close to the point of care. These agents are used in imaging for a variety of medical conditions, including cardiology, oncology and neurology.
Ionetix is also exploring additional applications for its particle accelerator technology beyond isotope production.
The Facts
-
2009
Incorporated
Delaware.
-
~75
People
Full-time employees.
-
2
Michigan sites
Corporate headquarters and cyclotron manufacturing, and therapeutic isotope production.
-
9
FDA PET sites
A production network spanning the United States.
FAQ
Ionetix leverages its proprietary cyclotron and accelerator expertise to produce a growing portfolio of critical medical isotopes for targeted alpha therapy and diagnostic imaging.
Ionetix is headquartered at 3130 Sovereign Drive, Lansing, Michigan, USA, and operates a network of nine FDA-approved PET production sites across the United States.
Ionetix was incorporated in Delaware in 2009.
Actinium-225 and astatine-211 for targeted alpha therapy, and nitrogen-13, fluorine-18 and gallium-68 for diagnostic imaging.
Investors